Decadel Chrono 500 mg 30 tablets

Tradename:

Dekadel Chrono

Decadel Chrono

Compound:

Each tablet contains:

sodium valproate 333 mg, which corresponds to the content of valproic acid 145 mg

Auxiliary components:

silicon dioxide, hypromellose 4000, ethylcellulose, sodium saccharinate, colloidal silicon dioxide.

Properties:

Antiepileptic drug. It is believed that the mechanism of action is associated with an increase in the content of GABA in the CNS, which is due to the inhibition of GABA transaminase, as well as a decrease in the reuptake of GABA in the brain tissues. This, apparently, leads to a decrease in the excitability and convulsive readiness of the motor areas of the brain. Helps to improve the mental state and mood of patients.

Indications:

Epileptic seizures: generalized, focal (focal, partial) with simple and complex symptoms, small. Convulsive syndrome in organic diseases of the brain. Behavioral disorders associated with epilepsy. Manic-depressive psychosis with a bipolar course, not amenable to treatment with lithium or other drugs. Febrile convulsions in children, children’s tick.

Dosage and administration:

The optimal dosing regimen is determined by the doctor. Compliance of the dosage form of a particular drug with indications for use and dosing regimen should be strictly observed.

Individual. For oral administration in adults and children weighing more than 25 kg, the initial dose is 10-15 mg / kg / day. Then the dose is gradually increased by 200 mg / day with an interval of 3-4 days until a clinical effect is achieved. The average daily dose is 20-30 mg/kg. For children weighing less than 25 kg and newborns, the average daily dose is 20-30 mg / kg.

Contraindications:

Severe liver dysfunction; severe dysfunction of the pancreas; porphyria; hemorrhagic diathesis; severe thrombocytopenia; I trimester of pregnancy; lactation (breastfeeding); hypersensitivity to valproic acid.

Precautionary measures:

Use with caution in patients with pathological changes in the blood, with organic diseases of the brain, a history of liver disease, hypoproteinemia, impaired renal function.

In patients receiving other anticonvulsants, treatment with valproic acid should be started gradually, reaching a clinically effective dose after 2 weeks. Then carry out a gradual abolition of other anticonvulsants. In patients not treated with other anticonvulsants, a clinically effective dose should be reached after 1 week.

It should be borne in mind that the risk of developing side effects from the liver is increased during combined anticonvulsant therapy.

Side effects:

From the side of the central nervous system: trembling of the hands or arms is possible; rarely – changes in behavior, mood or mental state, diplopia, nystagmus, spots before the eyes, impaired coordination of movements, dizziness, drowsiness, headache, unusual arousal, restlessness or irritability.

On the part of the digestive system: slight cramps in the abdomen or in the stomach area, loss of appetite, diarrhea, indigestion, nausea, vomiting are possible; rarely – constipation, pancreatitis.

From the blood coagulation system: thrombocytopenia, prolongation of bleeding time.

From the side of metabolism: an unusual decrease or increase in body weight.

From the gynecological status: menstrual irregularities.

Dermatological reactions: alopecia.

Allergic reactions: skin rash.

Storage method:

Store at a temperature not exceeding 30 degrees.

Package:

The cardboard box holds a plastic jar of 30 tablets.